Invex Therapeutics Ltd
Invex Therapeutics Ltd
Your view on IXC.AX
Overview
What the company does, where it operates, and who runs it.
About Invex Therapeutics Ltd
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Timothy Ryan Slate
- Headquarters
- 38 Rowland Street, Subiaco, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Timothy Ryan Slate
- Headquarters
- 38 Rowland Street, Subiaco, WA, AU
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials. The company was founded in 2019 and operates from Perth, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Invex Therapeutics Ltd, and the rating behind it. IXC.AX last traded at AUD 0.12; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Invex Therapeutics Ltd. Starting points for Invex Therapeutics Ltd: EPS -AUD 0.01, beta 0.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Invex Therapeutics Ltd. Invex Therapeutics Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Invex Therapeutics Ltd. Trailing twelve-month EPS for Invex Therapeutics Ltd stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Invex Therapeutics Ltd. Invex Therapeutics Ltd has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Invex Therapeutics Ltd valued side by side against its closest peers. Invex Therapeutics Ltd is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Invex Therapeutics Ltd, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Invex Therapeutics Ltd executives and directors. Shares of Invex Therapeutics Ltd have traded between AUD 0.07 and AUD 0.18 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Invex Therapeutics Ltd. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Invex Therapeutics Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Invex Therapeutics Ltd. Coverage tracks Invex Therapeutics Ltd within Biotechnology (Healthcare). Press releases and market coverage, newest first.